Recently, an extensive whole-genome CRISPR knockout screen of 7 B-ALL cell lines revealed system xc−—GSH—GPX4 axis to be a common therapeutic vulnerability in B-ALL, which is partially attributed to low levels of GSH and FSP1 in these cells [187]. This evidence concerns the gene AIFM2 and acute lymphoblastic leukemia.